Triptorelin for the treatment of endometriosis

Umberto Leone Roberti Maggiore, Scala C, Carolina Scala, Valentino Remorgida, Venturini PL, Pier Luigi Venturini, Fabio Del Deo, Del Deo F, Marco Torella, Colacurci N, Nicola Colacurci, Salvatore S, Stefano Salvatore, Ferrari S, Stefano Ferrari, Enrico Papaleo, Massimo Candiani, Simone Ferrero
Expert opinion on pharmacotherapy · 2014 · vol. 15(8) , pp. 1153–1179 · doi:10.1517/14656566.2014.916279 · PMID:24832495 · W2007878017
review OA: closed CC0 ⤵ 11 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Triptorelin, a GnRH agonist, effectively improves pain symptoms and reduces endometriotic nodule size in patients with endometriosis, with ongoing research into its pre-operative use.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. AREAS COVERED: This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. EXPERT OPINION: The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. Further, this effect is confirmed by the reduction in the volume of the endometriotic nodules during treatment. Future research should evaluate whether the pre-operative administration of triptorelin prior to surgical excision of endometriomas may be useful in preserving the ovarian reserve.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Luteolytic Agents Triptorelin Pamoate Animals Clinical Trials as Topic Drug Evaluation, Preclinical Endometriosis Female Humans Luteolytic Agents Luteolytic Agents Luteolytic Agents Treatment Outcome Triptorelin Pamoate Triptorelin Pamoate Triptorelin Pamoate

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (63)

Cited by (13)

Source provenance

europepmc
last seen: 2026-09-27T09:11:36.575535+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:29.016410+00:00
unpaywall
last seen: 2026-09-27T06:17:51.937953+00:00
License: CC0 · commercial use OK